Literature DB >> 10318271

Review of Canadian pharmacist involvement in adverse drug reaction reporting.

K M Taras-Zasowski, T R Einarson.   

Abstract

Adverse drug reaction (ADR) recognition, evaluation and reporting are important aspects of modern pharmacy practice. Pharmacists have the knowledge and responsibility to contribute to ADR reporting programs. A total of eight studies have reported the incidence of ADRs in Canadian hospitals. On average one in every six patients (17 percent) develop an adverse drug reaction. This may prolong hospital stay, increasing the cost of hospitalization by millions of dollars annually. Although ADR programs can be time consuming, the potential of reducing the financial burden of ADRs would be a positive outcome. A great opportunity exists for pharmacists to contribute in this area of patient care.

Entities:  

Mesh:

Year:  1989        PMID: 10318271

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN: 0008-4123


  5 in total

1.  Influence of pharmacists' attitudes on adverse drug reaction reporting : a case-control study in Portugal.

Authors:  Maria T Herdeiro; Adolfo Figueiras; Jorge Polónia; J J Gestal-Otero
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  Influence of attitudes on pharmacists' intention to report serious adverse drug events to the Food and Drug Administration.

Authors:  Paul Gavaza; Carolyn M Brown; Kenneth A Lawson; Karen L Rascati; James P Wilson; Mary Steinhardt
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

3.  Adverse Drug Reactions: Review of the Canadian literature.

Authors:  J Lexchin
Journal:  Can Fam Physician       Date:  1991-01       Impact factor: 3.275

4.  The role of pharmacists in adverse drug reaction reporting.

Authors:  P I Roberts; D J Wolfson; T G Booth
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

5.  Impact of a Policy Change on Pharmacists' Reporting of Adverse Drug Reactions.

Authors:  Renaud Roy; Janice Ma
Journal:  Can J Hosp Pharm       Date:  2018-08-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.